서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 41 to 58 of 58

Issue DateTitle / Author(s) / CitationFileAltmetrics
2020-03
The effects of letrozole on women with endometriosis undergoing ovarian stimulation for in vitro fertilization
DOI
2020-04
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
DOI
2020-04
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
DOI
2020-06
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): A randomised, open-label, phase 2 trial
DOI
2020-07
In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses
DOI
2020-09
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
DOI
2020-10
Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients
DOI
2020-10
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
DOI
2020-11
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
DOI
2020-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
DOI
2021-01
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
DOI
2021-01
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
DOI
2021-03
Development and Evaluation of an Inter-professional Education Course at a Medical School in Korea

Kim, Chan Woong; Eo, Eun Kyung; Myung, Sun Jung

Journal of Korean Medical Science, Vol.36 No.9, p. e69

DOI
2021-09
The relationship between the effect-site concentration of propofol and sedation scale in children: a pharmacodynamic modeling study
DOI
2022-02
Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
DOI
2022-02
Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients
DOI
2022-07
Different levels of humoral and cellular immunity to varicella-zoster virus in seropositive healthcare workers
DOI
2023-03
COVID-19 Vaccination in Korea

Park, Wan Beom; Hwang, Young Hoon; Cheong, Hee Jin

Infection and Chemotherapy, Vol.55 No.1, pp.135-149

DOI
1 2